X0609 4 2026-05-22 false 0001651308 BeOne Medicines Ltd. ONC 0001263508 BAKER BROS. ADVISORS LP false 860 WASHINGTON STREET, 3RD FLOOR NEW YORK NY 10014 true false false false 0001551139 667, L.P. false 860 WASHINGTON STREET, 3RD FLOOR NEW YORK NY 10014 true false false false 0001580575 Baker Bros. Advisors (GP) LLC false 860 WASHINGTON STREET, 3RD FLOOR NEW YORK NY 10014 true false false false 0001363364 Baker Brothers Life Sciences LP false 860 WASHINGTON STREET, 3RD FLOOR NEW YORK NY 10014 true false false false 0001087940 BAKER FELIX false 860 WASHINGTON STREET, 3RD FLOOR NEW YORK NY 10014 true false false false 0001087939 BAKER JULIAN false 860 WASHINGTON STREET, 3RD FLOOR NEW YORK NY 10014 true false false false false Ordinary Shares 2026-05-22 4 S false 2743 23.8512 D 145322 I See Footnotes Ordinary Shares 2026-05-22 4 S false 2743 23.8512 D 145326 I See Footnotes Ordinary Shares 2026-05-22 4 S false 2756 23.7905 D 142566 I See Footnotes Ordinary Shares 2026-05-22 4 S false 2756 23.7905 D 142570 I See Footnotes Ordinary Shares 1 D Ordinary Shares 1 D American Depositary Shares 10418 D American Depositary Shares 10418 D American Depositary Shares 730642 I See Footnotes American Depositary Shares 8068411 I See Footnotes On May 22, 2026, Michael Goller, a full-time employee of Baker Bros. Advisors LP (the "Adviser") sold 2,743 ordinary shares ("Ordinary Shares"), in the form of 211 American Depositary Shares of the Issuer ("ADS") of BeOne Medicines Ltd. (the "Issuer") at a price of $23.8512 per ordinary share or $310.0659 per ADS and Ranjeev Krishana, a full-time employee of the Adviser sold 2,756 Ordinary Shares in the form of 212 ADS at a price of $23.7905 per ordinary share or $309.2769 per ADS. The Ordinary Shares sold were received from the vesting of restricted stock units (each, an "RSU") that Michael Goller and Ranjeev Krishana were granted on May 21, 2025 as compensation for their service on the board of directors of the Issuer (the "Board"). Such sales were effected in connection with the vesting of such RSUs pursuant to mandatory tax withholding provisions in the applicable RSU award agreements. After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, L.P. ("667"), Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Ordinary Shares reported in column 5 of Table I held directly by or held for the benefit of 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667. Pursuant to the policies of the Adviser, Michael Goller and Ranjeev Krishana do not have any right to any of the Issuer's securities issued as compensation for their service on the Board and the Funds (as defined below) are entitled to an indirect proportionate pecuniary interest in such securities. The Funds (as defined below) each own an indirect proportionate pecuniary interest in the Ordinary Shares received upon vesting of RSUs and non-qualified share options convertible solely into Ordinary Shares of the Issuer ("Share Options") received as a result of their service on the Board. Solely as a result of their ownership interest in (i) the general partners of the Funds (as defined below) and (ii) the Funds (as defined below), Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the Ordinary Shares received upon vesting of RSUs, Share Options, and Ordinary Shares received upon the exercise of Share Options (i.e. no direct pecuniary interest). The Adviser serves as the investment adviser to 667 and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds"). In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit of the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds. Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by or held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose. Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the Share Options, RSUs and any Ordinary Shares received as a result of the exercise of Share Options or vesting of RSUs. The Ordinary Shares sold and reported on Table I represent a portion of the Ordinary Shares received by each of Michael Goller and Ranjeev Krishana upon vesting of RSUs granted on May 21, 2025. These sales, totaling 2,743 Ordinary Shares (211 ADS) for Michael Goller and 2,756 Ordinary Shares (212 ADS) for Ranjeev Krishana totaling 5,499 Ordinary Shares (423 ADS) in the aggregate, are reported for each of the Funds as each had an indirect proportionate pecuniary interest in such securities. Michael Goller and Ranjeev Krishana serve on the Board as representatives of the Funds and their affiliates and control persons. Includes beneficial ownership of 71,279 Ordinary Shares received from vested RSUs previously granted to Michael Goller, and 71,266 Ordinary Shares received from vested RSUs previously granted to Ranjeev Krishana, in their capacity as directors of the Issuer. After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker may be deemed to have an indirect pecuniary interest in the Ordinary Shares reported in column 5 of Table I directly held by or held for the benefit of Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences. Ordinary Share held directly by Felix J. Baker. Ordinary Share held directly by Julian C. Baker. Each ADS represents 13 Ordinary Shares. American Depositary Shares held directly by Felix J. Baker. American Depositary Shares held directly by Julian C. Baker. As a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the ADS reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667. As a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker may be deemed to have an indirect pecuniary interest in the ADS reported in column 5 of Table I directly held by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences. On May 27, 2025, BeiGene, Ltd. consummated redomiciliation transactions from the Cayman Islands to Switzerland and a name change pursuant to which BeOne Medicines Ltd. (the "Issuer") became the successor issuer to BeiGene, Ltd. Michael Goller and Ranjeev Krishana, full-time employees of Baker Bros. Advisors LP, are directors of the Issuer. By virtue of their representation on the board of directors of the Issuer, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the reporting persons are deemed directors by deputization of the Issuer. By: Baker Bros. Advisors LP, Name: Scott L. Lessing, Title: President /s/ Scott L. Lessing 2026-05-27 Baker Bros. Advisors LP, Mgmt. Co. and Inv. Adviser to 667, L.P., pursuant to authority granted by Baker Biotech Capital, L.P., GP to 667, L.P. Name: Scott L. Lessing, Title: President /s/ Scott L. Lessing 2026-05-27 By: Baker Bros. Advisors (GP) LLC, Name: Scott L. Lessing, Title: President /s/ Scott L. Lessing 2026-05-27 Baker Bros. Advisors LP, Mgmt. Co. and Inv. Adviser to BAKER BROTHERS LIFE SCIENCES, L.P., pursuant to authority granted by Baker Brothers Life Sciences Capital, L.P., GP to Baker Brothers Life Sciences, L.P., /s/ Name: Scott L. Lessing, Title: President 2026-05-27 /s/ Felix J. Baker 2026-05-27 /s/ Julian C. Baker 2026-05-27